A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice is a registry-stage clinical asset sponsored by Novo Nordisk A/S in Obesity. SEO and diligence focus: Semaglutide, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.